Company Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			Pre-market 08:42:41 am
7.070 ^USD	-4.20%		6.955	-1.63%

Dec. 09	Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants	RE
Dec. 08	Immix Biopharma Prices $100 Million Offering	MT

Business description: Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Number of employees: 20

Sales by Activity: Immix Biopharma, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024

See all business segments

Geographical breakdown of sales: Immix Biopharma, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024

See all geographic segments

Executive Committee: Immix Biopharma, Inc.

Manager	Title	Age	Since
Ilya Rachman CEO	Chief Executive Officer	53	2011-12-31
Gabriel Morris DFI	Director of Finance/CFO	39	2021-02-28
Graham Ross CTO	Chief Tech/Sci/R&D Officer	65	2021-05-31
Michael A. Grabow PRN	Corporate Officer/Principal	-	2025-11-11
Nandan Oza PRN	Corporate Officer/Principal	62	2017-04-30

See IMMIX BIOPHARMA, INC. governance

Composition of the Board of Directors: Immix Biopharma, Inc.

Director	Title	Age	Since
Ilya Rachman CHM	Chairman	53	2011-12-31
Gabriel Morris BRD	Director/Board Member	39	2021-02-28
Helen Adams BRD	Director/Board Member	66	2021-05-31
Jane Buchan BRD	Director/Board Member	61	2021-06-30
Jason Hsu BRD	Director/Board Member	51	2012-12-31
Magda Marquet BRD	Director/Board Member	66	2021-05-31
Carey Ng BRD	Director/Board Member	46	2019-10-31
Yekaterina Chudnovsky BRD	Director/Board Member	40	2023-08-21
Nancy Chang BRD	Director/Board Member	75	2025-09-07

Composition of the Board of Directors

Shareholders: Immix Biopharma, Inc.

Name	Equities	%	Valuation
Jason Hsu 14.47 %	4,858,913	14.47 %	21 M $
Yekaterina Chudnovsky 9.652 %	3,241,076	9.652 %	14 M $
Ilya Rachman 3.4 %	1,141,683	3.4 %	5 M $
Carey Ng 3.113 %	1,045,221	3.113 %	4 M $
Nancy Chang 2.737 %	918,880	2.737 %	4 M $

List of IMMIX BIOPHARMA, INC. shareholders

Company details: Immix Biopharma, Inc.

Immix Biopharma, Inc.

11400 West Olympic Boulevard

90064, Los Angeles

http://www.immixbio.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMMIX BIOPHARMA, INC.	-4.20%	+27.16%	+246.57%	+292.78%	237M
ARGENX SE	-6.82%	-10.44%	+15.85%	+88.81%	54.11B
INSMED INCORPORATED	+0.91%	-3.43%	+175.04%	+885.54%	42.02B
WUXI APPTEC CO., LTD.	+0.70%	+4.04%	+66.46%	+19.60%	39.6B
BIONTECH SE	-1.24%	-1.50%	-21.24%	-49.04%	22.8B
GENMAB A/S	+0.05%	-1.90%	+39.83%	-35.89%	19.5B
WUXI BIOLOGICS (CAYMAN) INC.	-3.11%	-1.52%	+87.73%	-33.32%	17.76B
AKESO, INC.	-6.67%	-6.59%	+88.18%	+185.50%	14.73B
SUMMIT THERAPEUTICS INC.	-2.33%	-4.04%	-1.46%	+437.31%	13.55B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-8.21%	-9.69%	+124.41%	-	13.14B
Average	-2.66%	+1.61%	+82.14%	+199.03%	23.74B
Weighted average by Cap.	-2.51%	-1.13%	+65.98%	+218.94%